Researcher Nonaka from DMPK BU to Present a Poster at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics

2025.10.07

Our researcher, Masami Nonaka from the DMPK Business Unit, will present a poster at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics, to be held from October 20 to 23, 2025, in Kyoto prefecture, Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name: the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics

Date & Time: October 22, 17:10 – 18:10 (JST)

Location: Kyoto International Exhibition Hall “Miyako Messe”

Title: DAR evaluation in mouse plasma using anti-human IgG immunocapture and intact mass spectrometry at the discovery stage

Presentation number: P-128

Presenter: Masami Nonaka, DMPK Business Unit

Presentation Summary
Antibody-drug conjugates (ADCs) are attracting attention as therapeutics that combine the target specificity of antibodies with the potent activity of cytotoxic drugs. In ADC development, the drug-to-antibody ratio (DAR) is a critical parameter that directly impacts both efficacy and safety. However, in the discovery stage, DAR analysis in vivo has been challenging, because target antigens and payload-specific antibodies are often not available for rodent pharmacokinetic studies. To address this challenge, we have developed a novel evaluation method that combines anti-human IgG immunocapture with intact mass analysis. This approach can acquire time-dependent DAR profiles of ADCs in mouse plasma without requiring target or payload specific reagents. Thus, our method enables efficient and rapid optimization of ADCs from the early discovery stage.

Axcelead DDP’s Soulution
Axcelead has extensive experience in ADC pharmacokinetic evaluation, immunocapture technology, and mass spectrometry analysis, providing seamless support from discovery through development. Even when target- or payload-specific antibodies are unavailable, our method that combines anti-human IgG immunocapture with intact mass spectrometry can acquire time-dependent DAR profiles from mouse plasma. These data can be used to analyze drug-release behavior and optimize candidate compounds. Please contact us if you face challenges in ADC DAR evaluation.